Reneo Pharmaceuticals, Inc. (RPHM) NASDAQ
18.20
+16.47(+952.02%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Reneo Pharmaceuticals, Inc.
Address
18575 Jamboree Road
Irvine, CA 92612
United States of America (the)
Phone
619 733 3852
Website
Sector
Healthcare
Industry
Biotechnology
Employees
8
First IPO Date
April 08, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Gregory J. Flesher | President, Chief Executive Officer & Director | 569,704 | 1970 |
| Michael G. Grey | Founder & Executive Chairman | 100,000 | 1953 |
| Ashley F. Hall | Chief Development Officer | 447,104 | 1972 |
| Alejandro Dorenbaum | Chief Medical Officer | 466,229 | 1961 |
| Michael Cruse | Chief Operating Officer | 535,474 | 1972 |
| Jennifer Lam | SVice President of Finance & Administration and Principal Financial & Accounting Officer | 0 | N/A |
Description
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
